Ammonia oxidizing microorganism preparations for delivery to the intranasal system, kits including ammonia oxidizing preparations for delivery to the intranasal system, and devices for administering ammonia oxidizing preparations to the intranasal system are provided. Methods of introducing ammonia oxidizing microorganisms to the intranasal system are provided. Methods of treating disorders, including neurological disorders, nasal or sinus disorders, and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.

The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml ; and a buffer, a protective agent, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.

The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing/treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.

The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing/treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.

The present invention belongs to the field of medicine, and relates to a compound

##STR00001##

of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

The present invention is directed to pharmaceutical products, and to methods for the treatment of depression (e.g., major depressive disorder) and other diseases or disorders for which esketamine has a therapeutic benefit. In some embodiments, the methods are useful for the treatment of treatment-refractory or treatment-resistant depression or suicidal ideation. Methods of intranasal administration and devices for intranasal administration are also disclosed.

This invention concerns anti-inflammatory agents, compositions, and methods for treating inflammatory disorders.

Described herein are tissue grafts derived from the placenta with improved physical and biological properties. In one aspect, the tissue graft includes a first membrane comprising Wharton's jelly laminated with amnion, chorion, or a combination thereof. The presence of Wharton's jelly in the grafts enhances the performance of allograft amniotic-derived, caderivic allograft, xenograft, or alloplast soft tissue substitutes.